Recent interest in therapies for sickle cell anemia based on elevating fetal Hb has made accurate estimates of the sparing effect offetal Hb (Hb F) and other non-sickle Hbs on sickle Hb (Hb S) polymerization essential. We have developed a technique, using HbCO as surrogate for HbO2, that enables us to assess the solubility of Hb S as a function of ligand saturation under conditions that mimic those of the sickling disorders. Equimolar mixtures of unliganded Hb S with Hb F or normal Hb A2 were isosoluble. Solubilities for equimolar mixtures with normal (Hb A) or abnormal (Hb C) Hbs were also identical but were lower than in the prior case. Thus, the sparing effect of both Hb F and Hb A2 should be considered in therapeutic strategies designed to modify Hb S polymerization. Hemolysates, stripped of 2,3-bisphosphoglycerate, from sickle cell disease patients with Hb (F + A2) levels varying from 6 to 25%, as well as from a sickle trait individual, were used to evaluate equilibrium solubiity as a function of ligand saturation over the range of pathophysiologic interest (25-70%). Our results show that the sparing effect of Hb (F + A2) increases relative to that of Hb A as ligand saturation increases, and that in the absence of ligand, '30% Hb (F + A2) is essentially isosoluble with the 60% Hb A of sickle trait. Although detailed knowledge of expected therapeutic benefits is confounded by the heterogeneity of Hb F distribution and other variables, these data should provide a framework for estimating likely clinical benefit from pharmacologic efforts to modulate globin gene expression.
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Sickle cell anemia exists in individuals who are homozygous for a point mutation (GAG --GTG) at codon 6 of the 3-globin gene, which results in a Glu-6 -* Val substitution in P-globin.
This transposition of a hydrophobic for a polar residue on the surface of sickle hemoglobin (Hb S; a2A32) results in a profound reduction of its solubility in the deoxy (T) conformation. Upon partial deoxygenation of Hb S-containing erythrocytes, such as occurs in the microcirculation, polymers of partially liganded Hb S are produced that perturb its rheological properties and lead to the characteristic vasoocclusive episodes of this disease. The clinical severity of the sickling disorders is modulated, however, by variations in the Hb composition of sickle cells that occur among individual patients. Therapies based on elevating fetal hemoglobin (Hb F; a2y2) have become a major focus of laboratory and clinical studies in the last few years. Two recent review articles (1, 2) provide an overview of the pathophysiology of sickling disorders and the intracellular polymerization process that underlies it.
Normal [Hb A (a2I3), Hb A2 (a2&2), and Hb F] and abnormal [e.g., Hb C(a2f3)] hemoglobins that may be present along with Hb S in human erythrocytes act to elevate its solubility under conditions of partial or total desaturation and The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
are, thus, said to have a "sparing" effect on intracellular Hb S polymerization (3, 4) . For Hbs F and A2, this solubilization can be described well with a model that assumes complete exclusion of either the homotetramer (a2-y2 or a2&2) or the hybrid heterotetramer (a238y or a2138) from the nascent polymer (5-7). For Hbs A and C, the data are compatible with exclusion of only homotetramers (a2I3A and a2K) from the polymer. Hybrid heterotetrameric forms (a2f3Sf3A and a2138S,c) appear to be incorporated into the polymer, but with a copolymerization probability roughly one-half that of Hb S (8-10). These copolymerization tendencies explain why the solubility enhancement induced by Hb F or A2 in admixture with Hb S is greater than that for Hb A or C.
The solubilizing properties of various non-S Hbs have been established by use of a chemical reducing agent (dithionite) to completely deoxygenate mixtures of oxy-Hb S and the oxy form of other hemoglobins (Hb X), followed by centrifugation to fractionate the resulting semisolid gel into a tightly packed polymer pellet and a supernatant consisting of soluble Hb S and Hb X. The concentration of all Hb species in the supernatant is by definition the saturation concentration (csat), or equilibrium solubility, under given in vitro conditions (11, 12) . This method has been used to assess the equilibrium interaction of various mixtures of totally unliganded Hb S and Hb X (8-10) and to screen potential antigelling agents that might be used to treat sickle cell disease (13) (14) (15) . However, the 02 tension of the mixed venous circulation, where vasoocclusive episodes occur, is estimated to range from 20 to 40 torr (1 torr = 133.3 Pa) (16) . No equilibrium solubility studies have yet been performed on mixtures of Hb S with non-S Hbs at 02 saturation values (25-70%) corresponding to these physiologic 02 tensions, mainly because of the difficulty in preventing MetHb formation during sedimentation experiments (17) .
In contrast to HbO2, however, HbCO is not autoxidizable to MetHb, and its use as a surrogate for the R state would obviate this problem. The solubility of Hb S as a function of ligand saturation is virtually identical (up to 85% saturation) for 02 and CO (17, 18) , indicating that the two ligands are interchangeable with respect to stabilization of the oxy (R) conformation of the allosteric equilibrium. Furthermore, sedimentation of mixtures of Hb S partially liganded with CO and unliganded Hb S results in a polymer phase from which HbCO is nearly completely excluded (18) (19) (20) use of this technique it has been possible to obtain a family of solubility profiles (Csat vs. fractional saturation with CO) for mixtures of Hb S with levels of Hb F varying from 3.5 to 22%. For this purpose, hemolysates, stripped of 2,3-bisphosphoglycerate, from sickle cell syndrome patients with variable expression of Hb F, and relatively constant levels of Hb A2 (-3%), were used. Such information will be vital for obtaining reliable estimates of the therapeutic efficacy expected from stimulation of Hb F synthesis by drugs such as hydroxyurea, erythropoietin, and butyrate analogues that are currently undergoing clinical trials as treatments for sickle cell disease (21) (22) (23) (24) .
MATERIALS AND METHODS General Methods. Total Hb was measured spectrophotometrically as cyanmethemoglobin (HiCN) by using the millimolar extinction coefficient of 11.0 cm-1 (per heme) at 540 nm (25) ; MetHb was measured (26) from the absorbance ratio A540 (before dithionite)/A555 (after dithionite). Hbs F and A2 in hemolysates were quantitated by alkali denaturation (27) and elution from DEAE-cellulose columns (28) Hemolysates of Hb S Plus Hb X. Three of the four hemolysates with various levels of Hb F (Table 1) were also obtained from the cryopreservation laboratory. Packed erythrocytes from an apheresis unit were thawed, and glycerol was removed. Hemolysates were prepared with toluene by the method of Drabkin (31) . For the hemolysate with the highest level of Hb F, whole blood from a patient undergoing hydroxyurea therapy at the National Institutes of Health (21) was used. Sickle trait blood (AS) was used to obtain a hemolysate suitable for evaluating the sparing effect of Hb A. Each hemolysate was dialyzed into isosmotic buffer contain- ing 0.05 M Bistris, 0.1 M KCl, and 0.02 M NaCl (pH 8.0 at 250C). Solubility Measurements. Details of the modification of our original csat assay method (11) to a microscale have been presented elsewhere (13, 14, 32) . A description of the precautions necessary to preserve anaerobicity during the handling of dithionite, as well as the rationale for the use of Bistris-buffered saline as a near-physiologic medium for the csat assay, has recently appeared (30) . Two sets of csat assay measurements were made, one for unliganded mixtures of Hb S plus Hb X in phosphate buffer, pH 6.5 at 30°C, and the other for Hb S as a function of ligand saturation at various levels of Hb (F + A2) in Bistris {2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)-1,3-propanediol} buffer, pH 7.2, at 37°C. In the latter case, a portion of the dialyzed HbO2 was converted to HbCO by equilibration with CO for 30 min in an Instrumentation Laboratory model 237 tonometer at 250C. Complete saturation was verified spectrophotometrically by use ofthe ratio A555/A540 after addition ofdithionite (33 
RESULTS
Purified samples of Hbs S, A, C, F, and A2 were used to assess the sparing effect of non-S Hbs on the solubility of fully unliganded Hb S in 0.15 M KPO4 buffer, pH 6.5 at 30°C. This buffer was chosen because previous studies addressed to this issue have used it (3, 4, 8, 9) or a variation (6, 7, 10), and any additional data must be compared with those analyses. The final pH after addition of dithionite (40-62 mM) falls within the region of csat invariance (6.2-6.8) demonstrated in an earlier study (30) . Solubility profiles for each non-S Hb species are shown in Fig. 1 . Because the data were nearly linear in each case, regression analysis was used to obtain a measure of relative effectiveness (i.e., slope of Csat vs. mol fraction of Hb X for each species). The slopes for Hbs F and A2 are nearly identical (21.8 and 20.4 g/dl, respectively), as are the slopes for Hbs A and C (13.2 and 14.4 g/dl, respectively). Hb F and Hb A2 are thus equipotent in their sparing effect on the solubility ofunliganded Hb S. To a lesser extent, Hb A and Hb C are also equipotent in their ability to inhibit polymerization.
Whole blood hematologic parameters for the four sickle cell syndrome patients and one sickle trait individual used in this study are summarized in varied from 6 to 25% in hemolysates from the four patients. Non-S Hb levels for the AS phenotype were 60.7% (A), 2.6% (A2), and 0.5% (F) . Mean corpuscular Hb concentration (MCHC) values were in the normal range (33.1-35.0 g/dl), except for patient Bi, whose MCHC was 28.8 g/dl due to the microcytosis of iron deficiency (34) .
Because the phosphate buffer used to obtain the data of Fig. 1 was nonphysiologic with respect to pH, ionic strength, and temperature, the more physiologic Bistris-based buffer used earlier (30) was chosen for evaluating solubility as a function of CO saturation at various levels of Hb (F + A2).
The plots of measured csat vs. XCO for the six hemolysates of Table 1 are shown in Fig. 2a . These solubility profiles are approximately linear in each case (range of correlation coefficients, r, from regression analyses: 0.974-0.992), with each curve displaced upward by the difference in solubility (Acsat) at zero CO saturation due to the increment in Hb (F + A2.) Data for the intercepts (c°at) and slopes of these plots are presented in Table 2 (columns 3 and 4). Because the solubility experiments reported in Fig. 2a Xco are presented in Table 2 (columns 5 and 6).
Comparison of the slopes for the original (Fig. 2a) and normalized (Fig. 2b) Csat data in Table 2 indicates that as the fraction Hb (F + A2) increases from 0.06 to 0.25 (Table 1 , patients A-D), the slopes decrease, but their magnitudes are greater for the original csat data (cf. the range of 17.9-13.8 g/dl vs. 12.6-9.6 g/dl for the slope parameter as X(F+A2) increases from 0.06 to 0.25). This presumably reflects the dependence of the measured csat values on ct and the particular value of ct chosen in each case (Ct/Csat 1.2 vs. ct = 34 g/dl). By use of the normalized c?,t values for unliganded mixtures of Hb S + Hb X (i.e., the intercept of each plot at Xco = 0), polymer mole fraction (fp) at zero saturation (fM was calculated from the conservation of mass relationship (37) for each hemolysate (see Table 2 footnote t). These values off°are collected in Table 2 Table 1 Fig. 2a . Values of ct, the total Hb concentration, were chosen such that the supersaturation ratio (Ct/Csat) had a mean value of 1.18 ± 0.05.
tLinear solubility profiles of Fig. 2b , based on c,,t values normalized to ct = 34 g/dl (see legend to Fig. 2) , were used to obtain these intercept (coat) and slope parameters. tfp at zero saturation was calculated from the conservation of mass equation (37), with values of 34 and 69.3 g/dl for ct and cp, respectively, and the appropriate normalized values of cst. §A sickle trait hemolysate; see Table 1 , footnote t.
uncertain. Hence, no attempt has been made to assign a CO saturation at which fp = 0 for each Hb fraction (F + A2). In general, the absence of polymer occurs at lower ligand saturations for the higher fractional Hb (F + A2) values.
DISCUSSION
The solubility profiles of Fig. 1 show that the sparing effect of either Hb F or Hb A2 on the polymerization of unliganded Hb S is substantially larger than that of either Hb A or Hb C.
Our findings with Hbs A and C confirm those of an earlier study (9) in which no significant difference was found in the tendency of Hb A or C to copolymerize with Hb S in the phosphate buffer (,u = 0.38) used here. The solubility of an equimolar mixture of Hb S plus Hb C measured in low-ionicstrength phosphate buffer (,u < 0.2) is, however, lower than that of a similar mixture of Hb S plus Hb A (39). The isosolubility of deoxy-Hb F or deoxy-Hb A2 in a 50:50 mixture with deoxy-Hb S confirms an earlier report to this effect (4) but is discrepant with others that report Hb A2 to be either less (7) or more (10) effective than Hb F in enhancing the solubility of unliganded Hb S. In any case, our results, in which buffer composition, pH, and temperature were care- (38) (29) at 37°C, the measured solubilities more closely mimic those ofthe intact cell. These studies assess the influence of non-S Hbs on the solubility of Hb S as a function of ligand saturation under conditions that approximate those of the sickling disorders. As such, they allow more precise predictions to be made of the therapeutic benefit to be derived from the hydroxyurea-induced elevation of Hb F (21) (22) (23) 42) . It should also be noted that with one exception (X(F+A2) = 0.063), the linear plots of the normalized csat data (Fig. 2b) tend to converge at higher fractional saturation values. This is particularly striking for the plots ofX(F+A2) = 0.25 and that for the AS hemolysate, which are displaced by 1.2 g/dl from each other at Xco = 0. Because the slope of the dependence of csat on Xco is greater (9.6 g/dl) for the mixture with Hb (F + A2) than for the AS hemolysate (7.6 g/dl; Table 2), they become coincident at a CO saturation near 40%o (see Fig. 2b ).
The corresponding value offp at this degree ofligation is 0.11. Because polymerization at each 02 saturation in the precapillary arterioles is believed important in the pathophysiology of this disease (1, 38) , the beneficial effect of Hb F elevation may be somewhat greater than previously estimated. This effect, however, is offset by the nonuniformity of the Hb F response to pharmacologic manipulation because the analysis is based on a uniform distribution of Hb F and MCHC, as well as of 2,3-bisphosphoglycerate content and intracellular pH.
Values of polymer fraction as a function of 02 saturation have been reported for both intact sickle trait erythrocytes (based on NMR spectroscopy) and an AS hemolysate (based on Csat measurements for gas-deoxygenated samples; refs. 36 and 43). The two sets of measurements were in very good agreement and gave mean values of 0.34 and 0.69 for f°?
and Xco (at fp = 0), respectively. These values are comparable to those of 0.25 and 0.66 obtained in the present study for a sickle trait hemolysate in which csat was measured as a function of CO saturation. This result attests to the correspondence of the solubilities of Hb S partially liganded with either 02 or CO when measured under comparable conditions.
Although no csat experiments were done with partially liganded Hb S in the absence of Hb F or A2, two reports addressed to this issue have appeared: one in which ligation was achieved with CO (19) and one with 02 (17) . The one (19) most relevant to our study evaluated csat as a function of CO saturation in 0.15 M Bistris buffer at 25°C. The slopes obtained were comparable to ours for the two hemolysates with the lowest Hb (F + A2) ( Sickle erythrocytes have a heterogeneous distribution of both MCHC and Hb F between "F" and "non-F" cells. Thus, low-Hb F cells would not achieve as great an inhibition of polymerization as high-F cells. Conversely, cells of higher MCHC (which decrease during therapy) would require an elevation of Hb F greater than posited above to reduce fp to that of deoxygenated AS erythrocytes (see Table 2 ). Although these calculations provide only first-order estimates of the sparing effect of Hb F, they nonetheless represent a significant advance over those previously available from modeling (38, 41) .
An earlier study (30) showed that two other cellular variables-2,3-bisphosphoglycerate content and pH-also affect polymerization in interdependent fashion. Because the protons that stabilize the T-state and the polymer are oxylabile, deoxygenation alkalinizes the sickle erythrocyte, elevating intracellular pH from 7.13 to 7.41 (30) . Because SS erythrocytes are only partialty deoxygenated as they traverse the microcirculation, this pH increment is not fully realized. Nevertheless, the actual pH of cells in the capillary bed would probably be >7.2. Values of c4 , therefore, would be somewhat higher than those given in Table 2 because csat is strongly pH dependent in this region (30) . In addition, the binding of 2,3-bisphosphoglycerate in the ,3 cleft elicits a distortion of the T-state (44) that decreases csat by 1.6 g/dl (30) . Because the c?O values in Table 2 pertain to stripped deoxy-Hb S, the values for 2,3-bisphosphoglyceratesaturated Hb S would be lower by this amount. Although exact pH values cannot be assigned for partially deoxygenated SS erythrocytes, the expected solubility increment would be partially offset by the decrement due to 2,3-bisphosphoglycerate binding. Thus, the final solubilities of mixtures of Hb S with Hb (F + A2) at the P02 of tissue capillaries (20-40 torr) should be close to those depicted in Table 2 .
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